Skip to content

Advertisement

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Systematic review of nephrotoxicity of drugs of abuse, 2005–2016

  • Kanaan Mansoor1,
  • Murad Kheetan1,
  • Saba Shahnawaz2,
  • Anna P. Shapiro3,
  • Eva Patton-Tackett1,
  • Larry Dial1,
  • Gary Rankin1,
  • Prasanna Santhanam4,
  • Antonios H. Tzamaloukas5,
  • Tibor Nadasdy6,
  • Joseph I. Shapiro1 and
  • Zeid J. Khitan1Email author
BMC NephrologyBMC series – open, inclusive and trusted201718:379

https://doi.org/10.1186/s12882-017-0794-0

Received: 18 April 2017

Accepted: 12 December 2017

Published: 29 December 2017

Abstract

Background

The United States is faced with an unprecedented epidemic of drug abuse. Every year thousands of Americans visit the emergency departments all over the country with illicit drug related complaints. These drugs have been known to be associated with a range of renal pathologies, from reversible acute kidney injuries to debilitating irreversible conditions like renal infarction. So far, no comprehensive study or systematic review has been published that includes the commonly used street drugs and designer drugs with potential nephrotoxic outcomes.

Methods

We conducted a systematic review of published case reports, case series, and cross sectional studies of nephrotoxicities related to drugs of abuse. Literature review was conducted using PubMed/Medline from January 1, 2005 -December 31, 2016 to search for publications related to drug abuse with a defined renal outcome. Publications which reported renal injury in relation to the use of illicit drugs were selected, specifically those cases with raised creatinine levels, clinically symptomatic patients, for instance those with oliguria and proven renal biopsies.

Results

A total of 4798 publications were reviewed during the search process and PRISMA flow chart and Moose protocol regarding systematic reviews were followed. 110 articles were shortlisted for the review. A total of 169 cases from case reports and case series, and 14 case studies were analyzed. Renal manifestations of specific illicit drug abuse were included in this review.

Conclusion

Based on the evidence presented, a wide range of renal manifestations were found to be associated with drug abuse. If the trend of increasing use of illicit drug use continues, it will put a significant percentage of the population at an elevated risk for poor renal outcomes. This study is limited by the nature of the literature reviewed being primarily case reports and case series.

Keywords

NephrotoxicityDrugs of abuseIllicit drugsAcute renal failure

Background

The United States is stricken by an unparalleled crisis of a drug overdose epidemic. In 2011 the National Center for Health Statistics (NCHS) reported that drug overdose death rates were fivefold higher as compared to the 1980s [1]. A survey by the National Survey on Drug Use and Health (NSDUH) in 2011 reported that 24.6 million Americans of ages 12 or older had used illicit drugs over the past month. This represented approximately 9.4% of the population aged 12 or older [2]. Opioids are the most common cause for deaths related to drug overdose while Marijuana is the most common illicit drug used in the United States [24].

According to the Drug Enforcement Agency (DEA), 17.2 billion units of opioids were dispensed at retail level during 2011 compared with 14.9 billion in 2015 [4]. A study estimated that the cost of opioid abuse can go as high as $53.4 billion to cover the legal cost, medical complications, criminal justice system and loss of productivity which is a major portion of the cost and amounts up to $ 42 billion [5]. New psychoactive drugs such as Synthetic Cathinones or Bath Salts are on the rise and patients with their toxicities are presenting to the EDs; they are derivatives of pyrrolidinopropiophenone [MDPV] or mephedrone [6]. They are not commonly tested for during drug screening and are available as various products not yet labeled as controlled substances, allowing a “legal high”. Thus they have a higher affinity for abusers as well as peddlers [4].

There is a wide range of renal manifestations in subjects exposed to elicit drugs ranging from prerenal azotemia to more severe functional and structural injuries. Rhabdomyolysis is a common cause of acute kidney injury (AKI) which is incited by a number of reasons such as prolonged immobilization as seen in opioid users [7]. Rhabdomyolysis is also evident in patients presenting with synthetic cannabinoids and synthetic cathinones abuse but these patients have rhabdomyolysis possibly due to exertional muscular breakdown [810].One of the notable causes of renal injury in drug abusers is an increase in the sympathomimetic activity which leads to generalized vasoconstriction and ischemic renal injury; this scenario is usually witnessed in patients with cocaine and methamphetamine abuse [1113]. Newer opioids and methamphetamines can cause thrombotic microangiopathy (TMA) [14].

Direct renal injury due to illicit drugs have been suggested but most of the reported direct injury is by mode of glomerular immunoglobulin and amyloid deposition such as in heroin abusers [15, 16]. Adulterants such as levamisole which is used to cut cocaine is known for its immunomodulatory properties that can cause antineutrophil cytoplasmic antibodies (ANCA)-vasculitis [17, 18].

To our knowledge, there is no comprehensive report or systematic review that includes the commonly used street and designer drugs with potential nephrotoxic outcomes. In this review, we are summarizing the nephrotoxicities of common and emerging drugs of abuse.

Methods

Search strategy

Qualified health care professionals (KM, MK, SS) conducted the literature search in PubMed with the earliest time limit set at January 1, 2005 and latest time limit set at December, 31st 2016. The main literature search was conducted on 11/1/2016 and a secondary update search was carried out on 1/20/2017. Further relevant publications were identified from reference lists and those which fulfilled the inclusion criteria were included. Phrases and MeSH terms used for the search included were acute kidney injury; chronic kidney disease; renal failure; acute renal failure; chronic renal failure; nephropathy. These terms were tested against the names of all drugs under review specifically marijuana, synthetic cannabinoids, Heroin, opioids, vicodin, subutex, suboxone, morphine, methadone, tramadol, opana, norco, oxycontin, hydrocodone, oxycodone, cocaine, cocaine and levamisole, hallucinogens, methamphetamines, 3,4-methylenedioxymethamphetamine (MDMA), foxy, molly, ritalin, adderall, phencyclidine, ketamine, angel dust, Lysergic acid diethylamide (LSD), mescaline, magic mushrooms, peyote mushrooms, bath salts, cathinones, synthetic cathinones, benzodiazepines and Ativan.

Study inclusion criteria

All abstracts were evaluated by 2 independent reviewers (KM, MK) and the full-text article was procured only if one or both reviewers regarded it as a relevant publication. The reviewers were selected so as to avoid potential conflict of interest due to authorship. Publications which reported renal injury due to illicit drug use were selected, specifically those with 1) raised creatinine levels 2) clinically symptomatic patients for instance those with oliguria 3) proven renal biopsies. All case studies, case reports, case series and original articles (cross sectional, cohorts) in the English language were included. Articles in other languages were only included if a version translated in English was available. Only human based studies with specific renal outcomes attributed to drug abuse were included. CARE guidelines/methodology were adhered to.

Results

A total of 2846 publications were reviewed during the search process through PubMed/Medline while 1952 number of publications were reviewed through the reference list of selected articles. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (Fig. 1 PRISMA) flow chart and Meta-Analysis of Observational Studies in Epidemiology (MOOSE) protocol were followed. 110 articles were shortlisted for the review [19]. Two investigators independently screened all abstracts and assessed the studies for eligibility, then extracted data on specific drugs and their nephrotoxic effects. Selection of articles was based on the title and abstracts but in case of uncertainty, the entire text of an article was read. All literature was catalogued in Mendeley. The primary outcome assessed was the nephrotoxic effects of the abovementioned illicit drugs. A total of 169 cases from case reports and case series with clinical parameters and outcomes reported with or without kidney biopsy were included as shown in Table 1. Table 1 summarizes the different illicit drugs and their patient demographics, showing that a majority of the illicit drug users were male except for Levamisole adulterated cocaine cases. Cases came from a range of ages 2 years to 65 years. Cocaine and Synthetic Cannabinoids (SCB) abuse led to the highest systolic and diastolic blood pressures whereas in other cases there wasn’t such a marked increase or decrease. The pulse was raised with all drugs of abuse and cases mostly presented with gastrointestinal symptoms, hyperthermia, altered mental status or flank pain. Intravenous drug abuse was the most common route used. Where a renal biopsy was performed, the most common outcomes were acute/chronic interstitial nephritis and membranopoliferative glomerulonephritis (MPGN). Amphetamine, Cocaine and levamisole adulterated cocaine users were most likely to need dialysis and amphetamine users were most likely to succumb to death as compared to other illicit drug users.
Table 1

Summary of Case reports and Case series of Synthetic Cannabinoids, Bath Salts, Heroin, Amphetamines, Cocaine, Cocaine and Levamisole and CPD – Opioids

 

SCB [8, 22, 23, 97107]

Bath Salts [6, 9, 10, 92, 108112]

Heroin [15, 16, 35, 3740, 43, 113]

Amphetamine [13, 81, 85, 86, 8890, 114117]

Cocaine [11, 5763, 66, 71, 118128]

Cocaine & Levamisole [17, 70, 7276, 129133]

CPD Opioids [7, 14, 44, 45, 48, 134137]

# of Patients In Case Reports

47

11

35

16

22

15

23

Sex (M:F)

45:2 (n = 47)

10:1 (n = 11)

33:2 (n = 35)

12:4 (n = 16)

21:1 (n = 22)

7:8 (n = 15)

2:1 (n = 21)

Age Range (Years)

15–65 (n = 46)

25–45 (n = 10)

24–42 (n = 35)

2–37 (n = 16)

22–65 (n = 22)

22–63 (n = 15)

22–59 (n = 21)

Vitals

 Mean Systolic BP(mm/Hg)

140.9 (n = 21)

135.5 (n = 6)

109.8 (n = 5)

116.1 (n = 8)

170.7 (n = 17)

122 (n = 3)

110.3 (n = 3)

 Mean Diastolic BP (mm/Hg)

78.3 (n = 21)

69.3 (n = 6)

68.2 (n = 5)

71.5 (n = 7)

98.2 (n = 17)

73 (n = 3)

59.3 (n = 3)

 Mean Pulse (bpm)

91.7 (n = 11)

131.3(n = 8)

99.75 (n = 4)

161.1 (n = 14)

82.5 (n = 11)

96 (n = 3)

124 (n = 3)

Route of Administration

 Smoking

29.8% (n = 14)

0

2.9% (n = 1)

0

59.1% (n = 13)

66.7% (n = 10)

0

 Intranasal

0

18.2% (n = 2)

2.9% (n = 1)

0

18.2% (n = 4)

20.0% (n = 3)

0

 Oral

14.9% (n = 7)

27.3% (n = 3)

0

87.5% (n = 14)

0

0

26.1% (n = 6)

 Intravenous

0

27.3% (n = 3)

88.6% (n = 31)

6.25% (n = 1)

4.5% (n = 1)

6.7% (n = 1)

73.9% (n = 17)

 Not Specified

55.3% (n = 26)

27.3% (n = 3)

5.7% (n = 2)

6.25% (n = 1)

18.2% (n = 4)

6.7% (n = 1)

0

Clinical Presentation*

 Gastro-intestinal Symptoms

63.8% (n = 30)

9.1% (n = 1)

2.9% (n = 1)

6.25% (n = 1)

40.9% (n = 9)

26.7% (n = 4)

26.1% (n = 6)

 Altered Mental Status

25.5% (n = 12)

36.4% (n = 4)

8.6% (n = 3)

31.25% (n = 5)

4.8% (n = 1)

6.7% (n = 1)

17.3% (n = 4)

 Flank Pain

23.4% (n = 11)

0

0

0

27.3% (n = 6)

0

0

 Neuro-Muscular Symptoms

6.4% (n = 3)

9.1% (n = 1)

2.9% (n = 1)

0

0

0

13.0% (n = 3)

 Hyperthermia

2.1% (n = 1)

36.4% (n = 4)

2.9% (n = 1)

75% (n = 12)

13.6% (n = 3)

6.67% (n = 1)

0

 Seizures

2.1% (n = 1)

0

0

56.3% (n = 9)

0

0

0

 Other**

2.1% (n = 1)

63.6% (n = 7)

11.4% (n = 4)

12.5% (n = 2)

68.1% (n = 15)

80.0% (n = 12)

21.7% (n = 5)

Lab Parameters

 Mean Peak Serum Cr (mg/dL)

7.6 (n = 43)

7.25 (n = 11)

2.54 (n = 35)

3.31 (n = 16)

7.35 (n = 20)

6.9 (n = 14)

4.21 (n = 23)

 Range Peak Serum Cr (mg/dL)

2.6–21 (n = 43)

1.2–15.2 (n = 11)

0.8–11.26 (n = 35)

1.79–9.60 (n = 16)

1.3–17.3 (n = 20)

2–20.8 (n = 14)

1–14 (n = 23)

 Range Peak Serum CPK (U/L)

144–301,901 (n = 14)

1183–235,377 (n = 10)

3200–236,000 (n = 3)

863–196,000 (n = 14)

45–990,400 (n = 13)

4585 (n = 1)

17,680–86,000 (n = 4)

# of cases of ADAMTS%T Def.

0

0

0

0

0

0

0

 Serology- ANCA

0

0

0

0

0

73.3% (n = 11)

0

# of cases with Urinalysis

 Hematuria

34.4% (n = 11)+

80% (n = 4)B

61.8% (n = 21)C

100% (n = 3)E

75.0% (n = 12) G

84.6% (n = 11) H

100% (n = 4)K

 Proteinuria

68.8% (n = 22)+

40% (n = 2) B

94.1% (n = 32) C

100% (n = 3) E

56.25% (n = 9) G

76.9% (n = 10) H

75% (n = 3) K

 Eosinophils

12.5% (n = 4)+

0

0

0

6.3% (n = 1) G

7.7% (n = 1) H

0

Radiology (U/S, CT Scans)

 Abnormal

45.9% (n = 17) A

66.7% (n = 4)U

75% (n = 3)D

0% (n = 0)F

92.8% (n = 13)S

25% (n- = 1)J

33.3% (n = 1) L

Kidney Biopsy

 Done

38.3% (n = 18)

0

88.6% (n = 31)

6.25% (n = 1)

54.5% (n = 12)

86.7% (n = 13)

17.4% (n = 4)

Renal Biopsy Diagnosis

 Acute Tubular Necrosis

55.6% (n = 10)

0

0

0

0

0

0

 Acute/Chronic Interstitial Nephritis

33.3% (n = 6)

0

9.7% (n = 3)

0

33.3% (n = 4)

7.7% (n = 1)

0

 MPGN

0

0

41.9% (n = 13)

0

0

0

0

 Thrombotic Microangiopathy

0

0

0

0

25.0% (n = 3)

7.7% (n = 1)

100% (n = 4)

 Pauci Immune GN

0

0

0

0

0

76.9% (n = 10)

0

 Chronic / Hypertensive

5.6% (n = 1)

0

0

0

16.7% (n = 2)

0

0

 Renal Infraction

0

0

0

0

8.3% (n = 1)

0

0

 Thrombosis

0

0

0

100% (n = 1)

8.3% (n = 1)

0

0

 Crystals

5.6 (n = 1)[22]M

0

3.3% (n = 1)[43]N

0

0

0

0

 Amyloidosis

0

0

32.3% (n = 10)

0

0

0

0

 Others

0

0

12.9% (n = 4)T

0

8.3% (n = 1)[127]P

7.7% (n = 1)[132]R

0

Diagnosis of non-biopsy Pts.

 Acute Kidney Injury

29

11

4

14

5

2

19

 RPGNs

0

0

0

1

0

0

0

 Renal Infraction

0

0

0

0

5

0

0

 # of Patients Dialyzed

23.4% (n = 11)

27.3% (n = 3)

11.4% (n = 4)

40% (n = 6)

40.9% (n = 9)

40.0% (n = 6)

17.4% (n = 4)

 Death as end point

4.25% (n = 2)

9.1% (n = 1)

14.3% (n = 5)

68.8% (n = 11)

0

6.7% (n = 1)

17.4% (n = 4)

* Patients had more than one symptom at presentation;**others include: Dyspnea, SOB, weight loss, chest pain, skin lesions, immobility, urinary complaints like hematuria, anuria; (+ 32/47 cases had urinalysis; A 37/47 cases had imaging studies; B5/11 cases had urinalysis; C 34/35 cases had urinalysis; D 4/35 cases had imaging studies; E3/15 cases had urinalysis; F 2/15 cases had imaging studies; G 16/22 cases had urinalysis;H13/15 cases had urinalysis; J 4/15 cases had imaging studies; K4/23 cases had urinalysis; L3/23 had imaging studies. S14/22 cases had imaging studies U 6/11 had imaging studies) M Calcium oxalate crystals, N Heroin crystal nephropathy, T Proliferative GN, Granulomatous GN and MCD + IgA deposits (2,1,1 cases), p Good Pastures Syndrome, R Membranous Nephropathy, S RPGN, T ADAMTS (A Disintegrin And Metalloproteinase with a Thrombospondin type 1 motif),

Fourteen case studies and analyzed case series were identified as shown in Table 2. A case series based on 456 SCB users showed AKI and rhabdomyolysis as the outcomes when SCB were used solely. Heroin users had a high probability of developing amyloidosis, nephrotic syndrome and progression to end-stage renal disease (ESRD). They also had a higher chance of developing rhabdomyolysis as compared to non- Heroin users and were seen to be co-infected with hepatitis C virus (HCV) as well as Human Immunodeficiency Virus HIV. Controlled prescription drugs (CPD) opioids were significantly shown to lead to renal failure (p < 0.001) A post mortem case series on cocaine users showed hypertensive- ischemic nephropathy in most cocaine users. Levamisole adulterated cocaine users were prone to be anti-neutrophil cytoplasm antibodies (ANCA) positive after long term drug use with a 100% prevalence of anti-myeloperoxidase antibodies. Amphetamine case series showed varied effects such as rhabdomyolysis leading to renal failure, malignant hypertension with hypertensive changes on biopsy and in one case series, death of all the subjects due to AKI and rhabdomyolysis.
Table 2

List of Clinical studies and Analyzed Case Series of Synthetic Cannabinoids, Bath Salts, Heroin, Amphetamines, Cocaine, Cocaine and Levamisole, CPD Opioids

Author, Year

Type of Study

Results

Misc Findings

Synthetic Cannabinoids

Reiderer et al., CDC, 2016 [138] n = 456

Cross Sectional

Cases involving Synthetic Cannabinoid Use = 456

Sole agent =277; SCB as agent in multi-agent = 179;

AKI in Sole agent SCB = 4.0%;

Rhabdomyolysis in Sole agent SCB = 6.1%

N/A

Heroin

Connolly et al.,

2006 [36] n = 20

Cross Sectional

Amyloidosis = 100%

Nephrotic Syndrome = 95%

ESRD = 60%

Cr mean = 6.4 ± 4.2 mg/dl

Proteinuria mean = 7.3 ± 4.1 g/24 h

CRP** mean (μmol/l) = 61.4 ± 64

Garg et al., 2011 [41], n = 367

Prospective Cohort Study+

Heroin use- HR 1.18 (0.75, 1.87) p = 0.43*

Model 2- Heroin −1.62 (1.01, 2.60) p = 0.045**

Model 4- Heroin- 1.28 (1.07, 2.87) p = 0.352**

Model 5- Heroin- 0.97 (0.53, 3.71) p = 0.910**

216 HIV+ HCV Confection cases

151 HCV Monoinfection cases

Kosmadakis et al., 2011 [139] n = 21

Case Control

Case =11,

Control = 10

Heroin Users (HU) with Rhabdomyolysis = 11

Non-Heroin Users(NHU) with Rhabdomyolysis =10

Rhabdomyolysis Severity HU > NHU

HU v/s NHU CPK# = p 0.039

HU v/s NHU LDHZ = p 0.031

HU v/s NHU PO4 = p 0.002

Novick et al.,

2016 [42] n = 2286

Cohort Study

Opiate users = 15%, Cocaine users = 22%

Odds of albuminuria:

Opiates: OR 1.20, 95% CI 0.83–1.73

Cocaine: OR 1.80, 95% CI 1.29–2.51

Odds of reduced eGFR:

Opiates: OR 2.71, 95% CI 1.50–4.89

Cocaine: 1.40, 95% CI 0.87–2.24

CPD Opioids

Briggs, 2013 [49] n = 33

Case Control

Case-15

Control-18

4/8 TTP without infection patients in the case group had renal failure and 7/7 TTP infection patients in the case group had renal failure.

(Odds ratio = 35.0; 95% confidence interval = 3.9–312.1) between TTP-like illness and injection of reformulated Opana ER

Aghabiklooei et al., 2014 [140]

n = 322

Cross Sectional

Acute methadone toxicity – Total n = 322, Survivors n-294, Non survivors n- 28

Acute Renal failure: total 16 (4.9%), Survivors 3 (1%), Non Survivors 13 (46.4%) p < 0.001

Rhabdomyolysis: Total 15 (4.6%), Survivors 7 (2.4%), Non-Survivors 8 (28.6%)

Glanzmann et al., 2015 [47]

n = 200

Case Control

Case = 100

Control =100

AKI with morphine – OR- 2.4 (1.02, 6.03) p = 0.042

AKI with opioids drug group- OR 3.2 (1.35, 7.75) p = 0.008

Age and sex was matched in cases and controls

Cocaine

Buettner et al.

2014 [55]

Case Series

(autopsy)

75/129 cocaine positive subjects

Signs of glomerular ischemia with cocaine = OR 3.08 (1.35–7.01) p = 0.007 *; OR = 3.34 (1.37–8.14) p = 0.01**.

Arteriosclerosis with cocaine = OR 2.35 (1.08–5.11) p = 0.02*; OR 3.88 (1.49–9.92) p = 0.005**

HTN-Ischemic Nephropathy with cocaine = OR 5.42 (1.17–25.20) p = 0.02*, OR = 6.0 (1.27–28.44) p = 0.02**

Cocaine and Levamisole

McGrath et al.

2012 [141]

Cross sectional

30/327 New ANCA patients

100% had antimyeloperoxidase antibodies and 50% antiproteinase 3 antibodies, 2 cases had acute renal failure.

N/A

Amphetamines

Liechti et al., 2005 [142] n = 52

Case Series

90.4% used drugs in combination with Ecstasy

3 patients had rhabdomyolysis and 1 patient had acute renal failure

N/A

CDC 2010 [83]

Case Series

One patient had renal failure, rhabdomyolysis and seizures who was admitted to the ICU and required hemodialysis.

N/A

Jones et al., 2015 [143]

Cross Sectional

Methamphetamine User: N = 47, Malignant Hypertension present in 89.45 (n = 42), CKD was present in 95.7% (N = 45) (55.3% had stage 5 CKD, 8.4% had stage 4 CKD, 10.6% had stage 2 CKD and 12.8% had stage 1 CKD)

Biopsy Findings- Biopsy was performed on 24 patients, Hypertensive changes were present in 50% (N = 12) (with N = 6 had malignant changes), 25% (N = 6) had ESRD, MPGN Type 1 with IgM-C3 deposits was found in 58.3% (N = 14), 37.5% (N = 9) had IgG deposits and 29% (N = 7) had IgA deposits.

Nicol et al. 2015 [87]

Case Series

All subjects’ death. 17/27 died after arrival to hospital.

85% AKI

54% Rhabdomyolysis

Median Peak Cr was 2.4 (1.7–12.8) mg/dl; Median Peak CK was 8200 (1952–237,960) U/L

+Several models used to assess risk of AKI due to concern for collinearity between Heroin, cocaine and alcohol

* univariate analysis, ** multivariate analysis

**CRP- C reactive protein, Z lactated dehydrogenase, # Creatinine phosphokinase

Seven cases of hyperemesis were gathered during the data search with their clinical parameters as shown in Table 3, while 6 cases of N-methyl-D-aspartate receptor (NMDA) receptor agonist from two studies were tabulated in as shown in Table 4. Renal biopsy findings in selected patients with drug abuse are shown in Fig. 2. Data presented are specified by type and route (if reported) of drug exposure. Units of laboratory values are all presented in SI units.
Table 3

Case reports of Marijuana induced Hyperemesis Syndrome

Author, Year

Age/Sex

Drug

Clinical Presentation

Findings

Findings

Price et al., 2010, [144] n = 1

30/M

Marijuana

Abdominal Pain, Nausea, Vomiting

Cr-3.2 mg/dL

Urinalysis-Trace ketones

Acute Kidney Injury

Baron et al., 2011 [145] n = 1

28/M

Marijuana

Vomiting

Cr-5.9 mg/dL

Acute Kidney Injury

Abodunde et al., 2013, [146] n = 1

36/M

Marijuana

Nausea, Vomiting, lethargy

Cr-9.06 mg/dL

Acute Kidney Injury

Chang et al., 2013 [147] n = 1

50/M

Marijuana

Vomiting, epigastralgia, Altered consciousness

Cr-10.1 mg/dL

Urinalysis-PH 5.5 with bland sediment

Acute Kidney Injury

Ukaigwe et al., 2014 [148], n = 1

38/M

K-2

Abdominal Pain, Nausea, Vomiting

Cr-4.78 mg/dL,

Pre renal acute kidney Injury

Habboushe et al., 2014 [24] n = 1

25/M

Marijuana

Nausea, Vomiting

Cr-3.21 mg/dL

Acute Kidney Injury

Srihari et al., 2016 [149] n = 1

43/M

Cannabis

Epigastric pain, Nausea, Vomiting

Cr-2.54 mg/dL

Acute Kidney Injury

Table 4

Case Report and Case Series of NMDA Receptor Antagonists

Author, year

N, Age/Sex

Drug

Clinical Presentation

Findings

Diagnosis

Wiergowski et al., 2014 [150]

31/M

Methoxetamine,

Amphetamines

“lack of Information”

Peak Cr- 3.56 mg/dL

Peak CK- 129,800 U/L

Anuria +ve

Acute renal failure secondary to rhabdomyolysis

Chenoweth et al.,

2015 [96]

27/M

Gacyclidine

Confused, combative

Peak Cr- 1.84 mg/dL

Peak CK- 2413 U/L

Acute kidney injury and rhabdomyolysis

 

49/M

Gacyclidine

Agitated

Peak Cr- 2.07 mg/dL

Peak CK- 28,305 U/L

Acute kidney injury and rhabdomyolysis

 

47/M

Gacyclidine

Difficulty in ambulating

Peak Cr- 3.84 mg/dL

Peak CK- 13,923 U/L

Acute kidney injury and rhabdomyolysis

 

47/M

Gacyclidine

Agitated and confused

Peak Cr- 1.47 mg/dL

Peak CK- 1780 U/L

Acute kidney injury and rhabdomyolysis

 

47/M

Gacyclidine

Found unconscious next to a gas station

Peak Cr- 5.9 mg/dL

Peak CK- 62,694 U/L; Dialysis +ve

Acute kidney injury and rhabdomyolysis

Figure 1
Fig. 1

PRISMA 2009 Flow Diagram

Figure 2
Fig. 2

a Segmental glomerular necrosis and early crescent formation (arrow) in a heroin abuser who developed glomerulonephritis secondary to MRSA tricuspid endocarditis. There were glomerular IgA and C3 deposits. The patient was also ANCA positive, which may occur in Up to 30% of patients with endocarditis associated glomerulonephritis. b Heavy glomerular amyloid A protein deposits (brown color) in an IV drug user and “skin popper” who presented with nephrotic syndrome and was diagnosed with AA amyloidosis. Immunoperoxidase stain with antibody to Amyloid A protein. c Severe obliterative vascular changes secondary to chronic stage thromobotic microangiopathy in a young patient with Opana abuse. d Myoglobin positive (brown) casts in a young female patient with heavy cocaine use and acute kidney injury. Her CK on presentation was 120,000 and her serum creatinine was 7.9 mg/dl. Immunoperoxidase stain with an antibody to myoglobin

Discussion

Marijuana

The psychoactive compound in marijuana is Delta-9-Tetrahydrocannabinol [20, 21]. While synthetic cannabinoids do not have anything in common with marijuana chemically, they can bind to cannabinoid receptors peripherally and in the central nervous system.

Synthetic cannabinoids are known to cause AKI but the exact mechanism is still unclear. As shown in Tables 1&2, several reports have documented specific renal pathologies mainly acute tubular necrosis (ATN) and acute interstitial nephritis (AIN) with some accompanied clinically by rhabdomyolysis. Extreme state of volume depletion because of recurrent vomiting and extreme dehydration along with immobilization can be the precipitating factor.

Bhanushali and Kamel et al. reported that apart from ATN, calcium oxalate crystals were also present upon biopsy. Kamel et al. proposed that as plants are used along with synthetic cannabinoids, there is a possibility that these plants may be oxalogenic and could lead to formation of oxalate crystals which could lead to renal injury. Direct nephrotoxicity of the synthetic cannabinoids remains as yet to be seen [22]. A slightly varied presentation was seen in a patient with Tubulo-Interstitial Nephritis and Uveitis (TINU) syndrome [23].

Although synthetic cannabinoids are the obvious culprits behind these toxicities, chronic use of marijuana can also lead to “Cannabinoid Hyperemesis Syndrome” which results in extreme hypovolemia that leads to severe prerenal azotemia [24] (see Table 3). In general, prerenal AKI in such patients is mostly reversible and remains in question regarding its long term renal sequelae but Coca et al. reported in their systemic review that the chances of developing chronic kidney disease (CKD) increase by 9 fold and the chances of end stage renal disease (ESRD) increase by 3 fold, in comparison to people who have never had an AKI [25].

Opioids

Heroin use has been known to cause nephropathy since the early 1970s, as reported by the Kings County Hospital in Brooklyn, NY and the term heroin-associated nephropathy (HAN) was coined [26, 27]. Details of reported renal effects of opioids are summarized in Tables 1 & 2.

HAN has been studied in detail but no specific facts have come to light as to whether heroin, morphine, cocaine, adulterants or diseases such as HCV, Hepatitis B virus (HBV) or HIV were responsible for the renal morphological changes [28]. Even though the Heroin epidemic is on the rise, HAN is at an overall decline and it has been debated that HAN predated the investigations of HCV and HIV [29]. It was postulated that chronic use of heroin or its vehicle incites an undefined response which leads to focal glomerulosclerosis with glomerular IgM deposition [30], resulting in nephrotic syndrome [31]. Turgutalp et al. reported a patient who used Heroin thrice a week for 2 years, and on biopsy the patient had minimal change disease with IgA-C3 4+ and IgG 1+ depositions [16].

Do Samerio et al. reported MPGN type I to be the most dominant type of disease present in Caucasian Heroin abusers, but the sample selected for the study had a positive HCV serology [15]. Thus, despite being a valuable resource, their study cannot demarcate whether the nephropathy should be attributed to Heroin use or HCV. Older studies suggest that focal segmental glomerulosclerosis (FSGS) was the most common type of nephropathy in heroin users in the 1970s [27, 32]. Detailed pathologic mechanisms are beyond the scope of this study and can be found elsewhere [29]. Recently, endocarditis associated glomerulonephritis has become an increasingly common disease in IV drug (heroin) users. It is almost always right sided and is associated with variable degree of glomerular immune complex deposition. Crescents can be seen in approximately 50% of the cases and 25 to 30% of patients are ANCA positive. Therefore, differentiating endocarditis-associated crescentric glomerulonephritis from ANCA vasculitis-associated crescentric glomerulonephritis can be difficult, particularly if the glomerular immune complex deposition is mild, which can happen in endocarditis-associated glomerulonephritis. Figure 2a illustrates kidney biopsy of a heroin abuser with segmental glomerular necrosis and early crescent formation.

Amyloidosis has been documented in heroin users [33, 34]. In 2009, a study demonstrated that all 9 patients had renal amyloidosis but all were HCV serology positive [35]. In 2006 Connolly et al. studied renal amyloidosis in intravenous drug users, but their work was limited due to the fact that it was not specified as to whether heroin or cocaine was used, and secondly only patients with amyloidosis were chosen for the study. 90% of the patients had nephrotic syndrome at presentation, 95% patients had HCV antibodies and 5% had HIV [36]. Recently, a case reported by Cooper et al. found serum amyloid A protein deposits and AIN in a Heroin abuser of 18 years [37]. Figure 2b illustrates the kidney biopsy with heavy glomerular amyloid A protein deposits of an IV drug abuser diagnosed with AA amyloidosis.

AKI due to Heroin has been attributed to rhabdomyolysis [38]. A case report by Gupta in 2011 reported rhabdomyolysis associated with AKI [39]. Similarly Abdullah et al. reported rhabdomyolysis and compartment syndrome in their patient who was also concomitantly using cocaine [40]. Grag et al. studied the incidence and predictors of AKI in 367 cases with HCV and HIV coinfection, and reported that after adjustments, Heroin has a slightly significant HR of 1.62(1.01,- 2.60) p = 0.05, but loses statistical significance when cocaine use is subsequently added into the model with a hazard ratio (HR) of 1.28 (0.76–2.14)p = 0.35 [41]. Meanwhile, a prospective cohort study reported that reduced eGFR was associated with Heroin [42]. Lastly, a relatively new mode of AKI has come to light as “heroin crystal nephropathy” by Bautista et al. in 2015 [43]. This case showed that volume depletion along with elevated urinary pH leads to crystallization of Heroin or its metabolites in renal tubules. Heroin being adulterated with sodium bicarbonate is the likely explanation [43].

It has been reported that Heroin addicts, when put on a methadone rehabilitation program, presented to the emergency department with fatigue and myalgia or at times unconsciousness, were found to have AKI with rhabdomyolysis. Primarily this occurs due to prolonged immobilization. [7, 44, 45].

Another unusual mode of AKI has been reported amongst infants and pediatric age groups; a 27-week-old infant developed hydronephrosis and bladder distension following morphine infusion with normalization of renal function once the infant was catheterized and morphine was stopped [46]. Glazmann et al. reported that the odds ratio (OR) of developing AKI in the pediatric intensive care unit (PICU) when morphine was being administered was 2.4 (1.02–6.03) p = 0.04 [47].

In recent years, many cases of oxymorphone or OPANA ER misuse by addicts have been reported. This is achieved by crushing and mixing the pill with water and injecting the said drug. OPANA-ER has been associated with thrombotic microangiopathy (TMA), with or without the presence of infection. A case series by Miller et al. reported 9 out of 18 patients who used oral OPANA-ER intravenously developed a TTP-like condition and had AKI [48]. A study by Center of Disease Control (CDC) in 2013 showed that the odds of developing TMA (TTP-like illness) with misuse of OPANA was OR 35 (3.9–312.1)p < 0.01 [49]. Further studies are required to fully understand the roll of OPANA in this condition. Figure 2c illustrates severe obliterative vascular changes secondary to chronic stage TMA in a young patient with Opana abuse.

Cocaine

Cocaine use has increased in the United States in 2014–2015 due to the increase in cultivation of Coca in Colombia, but these levels are still below the 2006 levels [4]. Cocaine seizures have increased and reached their highest since 2010; this is an indicator for increased cocaine availability. The per gram price of cocaine surged to its highest in the first quarter of 2015, while the purity of cocaine is at its all-time low [4]. Levamisole, dexamisole and fentanyl are the usual adulterants found in cocaine seized by the DEA [4]. Cocaine is available in two forms; as a salt (powder) with HCL and as an insoluble free base which is used as crack [20].

Vasoconstriction caused by cocaine is thought to result from uptake inhibition of catecholamines, serotonin and dopamine and increased release of norepinephrine from the adrenal glands. This surge of catecholamines increases alpha adrenergic stimulation which causes vascular smooth muscles to constrict [50, 51]. Cocaine up regulates vascular endothelin-1 receptors which causes decreased renal blood flow and GFR [29, 52, 53]. Sustained cocaine-induced vasoconstriction has devastating effects that lead to renal hypertension even without signs of systemic hypertension. This hypertensive state causes renal damage and leads to kidney failure [54, 55]. Cocaine may also cause platelet adhesion and microaggregates [56]. Detailed mechanisms and pathogenesis are beyond the scope of this study and can be found in studies by Zimmerman et al. and Jaffe et al. [29, 53]. A combined effect of these proposed mechanisms can cause cocaine-induced renal infarcts (CIRI). Bemanian et al. reported lack of evidence of a thrombus or valvular vegetation and concluded that the vasoconstrictive effect and thrombogenicity of cocaine were the major causes of CIRI [57]. Madhira et al. reported bilateral renal infarction due to vasospasm, confirmed by angiography [58]. Similar cases were also reported [5962]. TMA has also been reported in relation to cocaine use. Two patients presenting with worsening renal function and hypertension, were shown to have no rhabdomyolysis on investigation, and a kidney biopsy confirmed the diagnosis of TMA [63]. It would be safe to propose that renal infarction should be in the differential diagnosis of severe abdominal pain developing in cocaine users.

Cocaine is associated with rhabdomyolysis [64, 65], but when co-abused with alcohol, liver metabolism leads to the formation of an active metabolite cocaethylene which is highly toxic in comparison to cocaine alone. Recently, a study reported AKI in a patient who co-abused alcohol and cocaine; this report recommended that clinicians should be aware of rhabdomyolysis in patients with a history of co-abuse [66]. Connor et al. reported that rhabdomyolysis was present in 33% of the cocaine users with the prevalence of severe rhabdomyolysis (CK > 10,000 IU/L) being 11% among cocaine users [67]. Renal biopsy findings are that of severe ATN with numerous eosinophilic, globular and frequently pigmented casts, containing myoglobin. Figure 2d illustrates the kidney biopsy finding of a patient suffering from myoglobinuric AKI with a CK of 120,000 U/L and a serum creatinine of 7.9 mg/dL.

Levamisole, a discontinued anti-helminthic drug, is a common adulterant used with cocaine. In 2009, 70% of cocaine in the USA had levamisole. Levamisole when used with cocaine increases the action of catecholamines on neuronal synapses. It also potentiates the reuptake inhibition effect of Cocaine. Adjunctive use of cocaine and levamisole either by smoking or sniffing has been associated with vasculitis [68, 69] Levamisole possesses immunomodulation properties and causes pauci-immune crescentric GN [20]. Usually, this is associated with myeloperoxidase (MPO) and proteinase-3 (PR3) antibodies. In addition, antinuclear antibody (ANA), lupus anticoagulant and low complement levels are detected in most patients [7076]. Immune complex glomerulonephritis (GN) has been described but in such case, an underlying infection should always be considered [20, 74]. A case by Neynaber reported that their patient developed a fulminant case of granulomatosis with polyangitis and PR3 antibody [17].Though the synergism between these two has not yet been fully understood, the toxicity of levamisole and cocaine combined, expedites their respective manifestations leading to severe disease. In Tables 1 & 2, we have listed case reports and studies where the renal effects of cocaine in different scenarios have been studied.

Methamphetamine

Methamphetamines especially MDMA are known to cause AKI by several mechanisms. The most common mechanism, also found to be the most prevalent throughout literature selected for this study, was myoglobinuria-associated tubular injury secondary to rhabdomyolysis [77]. Other commonly proposed renal effects include prerenal azotemia, malignant hypertensive nephropathy, hyponatremia and necrotizing vasculitis, while some novel mechanisms include TTP induced by MDMA and thrombosis [13, 7884].

Ago et al. reported a patient who collapsed minutes after he was injected with methamphetamine. Multi-organ failure and rhabdomyolysis followed, and a biopsy showed presence of myoglobin pigmentation in his kidneys and AKI [85]. Similarly, Lin et al. reported a patient who ingested 26 tablets of Ecstasy resulting in a tonic-clonic seizure and presented with hyperthermia [86]. CPK is a good indicator for the extent of rhabdomyolysis, which in our literature review ranged from 1672 IU/L to 196,000 IU/L in patients presenting with AKI. A case series documented that 18 of 27 patients had AKI and 50% of them had rhabdomyolysis [87]. Santoro et al. reported a dextroamphetamine user, whose intense workout routine led to the development of rhabdomyolysis but timely treatment protected her from renal injury [82]. Another cause of rhabdomyolysis reported by Davis et al. was attributed to serotonin syndrome [88].

Thrombosis, TTP and coagulopathy have also been reported in association with MDMA. Eldehni et al. reported a 22 year old male with worsening renal function and bilateral loin pain who was found to have a small venous thrombus in the corticomedullary junction [85]. Though the exact mechanism is not known, it would be fair to postulate that MDMA was the exacerbating agent in this case as it is known to cause coagulopathy combined with its sympathomimetic effects. Disseminated intravascular coagulopathy (DIC) has been reported as a common occurrence along with renal failure; five out of six AKI patients in a case series had DIC as well [89]. Recently reported, a patient after consuming Ecstasy rapidly developed AKI, rapidly progressive glomerulonephritis (RPGN) and TTP with a platelet count as low as 5000 /uL, followed by the patient’s death [90]. De Fallois postulated that there is similarity in the structure of MDMA and thienopyridines which are known to cause TTP. Necrotizing vasculitis from MDMA leading to ESRD was also reported in one patient by Bingham [84].

Bath salts – Synthetic Cathinones

AKI with mild rhabdomyolysis and hyperuricemia secondary to ingestion of bath salts has been reported and urinary sediment analysis revealed ATN [6]. Regunath et al. reported a patient who developed oliguric AKI coupled with mild rhabdomyolysis after ingesting bath salts. In this case supportive measures weren’t enough and continuous renal replacement therapy was required for a period of 48 h [9]. There have been more severe cases that resulted in DIC and rhabdomyolysis [91].

Multi organ failure has also been known to occur after injection of bath salts, with anuric AKI being the primary presentation. Continuous renal replacement therapy was required, followed up with intermittent therapy for a span of one month [92].

NMDA receptor antagonists

NMDA receptor antagonists, potent hallucinogens, are primarily used for their euphoric, anesthetic and hallucinogenic properties. PCP and Methoxetamine mostly cause AKI secondary to rhabdomyolysis, while Ketamine has been known to cause lower urinary tract dysfunction [77]. Peng et al. reported a 45-year-old male intranasal Ketamine user who had increased urinary frequency with urethral pain. In this patient, computed tomography showed bilateral hydronephrosis and decreased bladder capacity confirming the diagnosis of Ketamine induced uropathy [93]. Similar cases were also reported [94, 95].

As shown in Table 4, several reports have documented renal injury as a result of NMDA receptor antagonists. A case series by Cheoweth et al. based on Gacyclidine users (which is similar to Phencyclidine), reported that all patients had rhabdomyolysis and AKI [96].

Conclusion

The use of illicit drugs continues to surge and is approaching epidemic proportions throughout the United States. With nearly 10% of the population older than 12 having taken drugs for nonprescription purposes in the last month (2), new synthetic substances being introduced into the market and increased ease of access there will undoubtedly be a continual increase in the negative medical, financial and societal outcomes. The pathophysiology underlying renal injury from drugs of abuse continues to be delineated as research into this condition develops. Studies performed to date have elucidated specific mechanisms of injury. However, many of the studies are confounded by multiple illicit substance or comorbid conditions such as HIV or hepatitis. Continued resources, education and research are needed to fully understand the myriad of renal insults related to drugs of abuse.

Abbreviations

CPD: 

Controlled prescription drugs

MDMA: 

3,4-methylenedioxymethamphetamine

MDPV: 

Pyrrolidinopropiophenone

NCHS: 

National Center for Health Statistics

NSDUH: 

National Survey on Drug Use and Health

TTP: 

Thrombotic thrombocytopenic purpura

NMDA: 

N-methyl-D-aspartate receptor

AKI: 

Acute kidney injury

CPD: 

Controlled prescription drugs

ATN: 

Acute tubular necrosis

AIN: 

Acute interstitial nephritis

TINU: 

Tubulo-interstitial nephritis and uveitis

CKD: 

Chronic kidney disease

ESRD: 

End stage renal disease

HAN: 

Heroin-associated nephropathy

HCV: 

Hepatitis C virus

HBV: 

Hepatitis B virus

HIV: 

Human immune deficiency virus

MPGN: 

Membranoproliferative glomerulonephritis

FSGS: 

Focal and segmental glomerulosclerosis

TMA: 

Thrombotic microangiopathy

CIRI: 

Cocaine-induced renal infarcts

MPO: 

Myeloperoxidase

PR-3: 

Proteinase-3

ANA: 

Antinuclear antibody

GN: 

Glomerulonephritis

RPGN: 

Rapidly progressive glomerulonephritis

DIC: 

Disseminated intravascular coagulopathy

HR: 

Hazard Ratio

CDC: 

Center of Disease Control

PICU: 

pediatric intensive care unit

DEA: 

Drug Enforcement Agency (DEA)

OPANA ER: 

Extended release

PRISMA: 

Preferred Reporting Items for Systematic Reviews and Meta-Analyses

MOOSE: 

Meta-Analysis of Observational Studies in Epidemiology

SCB: 

Synthetic Cannabinoids

ANCA: 

Anti-Neutrophil Cytoplasm Antibodies

TINU: 

Tubulo-interstitial nephritis and uveitis syndrome

ANA: 

Antinuclear antibodies

Declarations

Acknowledgements

None.

Funding

No funding was required to conduct this systemic review.

Availability of data and materials

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Authors’ contributions

KM performed literature search, followed Fig. 1 Prisma flow chart and Moose protocol, reviewed literature and wrote first draft, MK reviewed literature, followed Fig. 1 Prisma flow chart, SS performed literature search and followed Moose protocol, APS made inference of the studies short listed for the review article and made important revisions, EP-T worked on the background and contributed in the writing of the NMDA and Cathinones, LD made critical revisions and added the conclusion, GR contributed in the writing of the discussion, PS made important revisions and fixed the flow of study, AT made critical changes to the discussion and Table 2, TN made critical suggestions and additions including the figure, JIS designed Table 1 and revised cocaine section, ZJK reviewed literature, provided close supervision to the work, modified first and final drafts, followed Fig. 1 Prisma flow chart and designed Table 1. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Need for approval was waived.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Joan C. Edwards School of Medicine, Marshall University, Huntington, USA
(2)
Aga Khan University Hospital, Karachi, Pakistan
(3)
The Case Western Reserve University, Cleveland, USA
(4)
Johns Hopkins University, Baltimore, USA
(5)
University of New Mexico School of Medicine, Albuquerque, USA
(6)
The Ohio State University, Columbus, USA

References

  1. Warner M, Hui Chen L, Makuc DM, Anderson RN, Miniño AM. Drug poisoning deaths in the United States, 1980–2008. 1980;Google Scholar
  2. Abuse S, Administration MHS. Results from the 2013 National Survey on drug use and health: summary of National Findings, NSDUH series H-48, HHS publication no. (SMA) 14-4863. Rockville. MD: Substance Abuse and Mental Health S. Google Scholar
  3. Rudd RA, Seth P, David F, Scholl L. Increases in drug and opioid-involved overdose deaths — United States, 2010–2015. MMWR. Morb Mortal Wkly Rep. 2016;65Google Scholar
  4. U.S Department of Justice, Drug Enforcement Administration.2016 National Drug Threat Assessment Summary 2016.Google Scholar
  5. Hansen RN, Oster G, Edelsberg J, Woody GE, Sullivan SD. Economic costs of nonmedical use of prescription opioids. Clin J Pain. 2011;27:194–202.PubMedView ArticleGoogle Scholar
  6. Adebamiro A, Perazella MA. Recurrent acute kidney injury following bath salts intoxication. Am J Kidney Dis. 2012;59:273–5.PubMedView ArticleGoogle Scholar
  7. Valga-Amado F, Monzón-Vázquez TR, Hadad F, Torrente-Sierra J, Pérez-Flores I, Barrientos-Guzmán A. Rhabdomyolysis with acute renal failure secondary to taking methadone. Nefrologia. 2012;32:262–3.PubMedGoogle Scholar
  8. Ergül DF, Ekemen S, Yelken BB. Synthetic cannabinoid “bonzai” intoxication: six case series. Turk Anesteziyoloji ve Reanimasyon Dern Derg. 2015;43:347–51.Google Scholar
  9. Regunath H, Ariyamuthu VK, Dalal P, Misra M. Bath salt intoxication causing acute kidney injury requiring hemodialysis. Hemodial Int. 2012;16:S47–9.PubMedView ArticleGoogle Scholar
  10. Mcneely J, Parikh S, Valentine C, Haddad N, Shidham G, Rovin B, et al. Bath Salts: A Newly Recognized Cause of Acute Kidney Injury. Nephrol. Artic. ID. Hindawi Publishing Corporation; 2012;2012:560854.Google Scholar
  11. Carrasco R, Salinas M, Rossel V. Rhabdomyolysis and acute renal failure after cocaine overdose: report of one case. Rev Med Chil. 2011;139:480–3.PubMedView ArticleGoogle Scholar
  12. Ago M, Ago K, Hara K, Kashimura S, Ogata M. Toxicological and histopathological analysis of a patient who died nine days after a single intravenous dose of methamphetamine: a case report. Legal Med. 2006;Google Scholar
  13. Jonathan D. Auten, Michael J. Matteucci. Methamphetamine Poisoning. CALL US -The Off. Newsl. Calif. Poison Control Syst. 2008;6.Google Scholar
  14. Ambruzs JM, Serrell PB, Rahim N, Larsen CP. Thrombotic Microangiopathy and acute kidney injury associated with intravenous abuse of an oral extended-release formulation of Oxymorphone hydrochloride: kidney biopsy findings and report of 3 cases. Am J Kidney Dis. 2014;63:1022–6.PubMedView ArticleGoogle Scholar
  15. do Sameiro Faria M, Sampaio S, Faria V, Carvalho E. Nephropathy associated with heroin abuse in Caucasian patients. Nephrol Dial Transplant Oxford University Press. 2003;18:2308–13.View ArticleGoogle Scholar
  16. Turgutalp K, Kiykim A, Karabulut U, Gursoy D, Gurses I. Reversible minimal change nephrotic syndrome and glomerular IgA deposition associated with nonparenteral heroin abuse: a case report. Med Princ Pract. 2012;21:492–4.PubMedView ArticleGoogle Scholar
  17. Neynaber S, Mistry-Burchardi N, Rust C, Samtleben W, Burgdorf WHC, Seitz MA, et al. PR3-ANCA-positive necrotizing multi-organ vasculitis following cocaine abuse. Acta Derm Venereol. 2008;88:594–6.PubMedGoogle Scholar
  18. McGrath MM, Isakova T, Rennke HG, Mottola AM, Laliberte KA, Niles JL. Contaminated cocaine and antineutrophil cytoplasmic antibody-associated disease. Clin J Am Soc Nephrol. 2011;6:2799–805.PubMedPubMed CentralView ArticleGoogle Scholar
  19. PRISMA [Internet]. [cited 2017 Jan 18]. Available from: http://www.prisma-statement.org/PRISMAStatement/Default.aspx
  20. Pendergraft WF, Herlitz LC, Thornley-Brown D, Rosner M, Niles JL. Nephrotoxic effects of common and emerging drugs of abuse. Clin J Am Soc Nephrol. 2014;9:1996–2005.PubMedPubMed CentralView ArticleGoogle Scholar
  21. Gurney SMR, Scott KS, Kacinko SL, Presley BC, Logan BK. Pharmacology, toxicology, and adverse effects of synthetic cannabinoid drugs. Forensic Sci Rev. 2014;26:53.PubMedGoogle Scholar
  22. Kamel M, Thajudeen BA. Case of acute kidney injury and calcium oxalate deposition associated with synthetic cannabinoids. Saudi J Kidney Dis Transpl. 2015;26:802–3.PubMedView ArticleGoogle Scholar
  23. Sinangil A, Celik V, Kockar A, Ecder T. Synthetic cannabinoid induced acute Tubulointerstitial nephritis and uveitis syndrome: a case report and review of literature. J Clin Diagnostic Res. 2016;10:31–2.Google Scholar
  24. Habboushe J, Sedor J. Cannabinoid hyperemesis acute renal failure: A common sequela of cannabinoid hyperemesis syndrome. Am J Emerg Med Elsevier Inc. 2014;32(690):e1–690. e2Google Scholar
  25. Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int. 2012;81:442–8.PubMedView ArticleGoogle Scholar
  26. Friedman EA, Rao TKS. Disappearance of uremia due to heroin-associated nephropathy. Am J Kidney Dis. 1995;25:689–93.PubMedView ArticleGoogle Scholar
  27. Rao TKS, Nicastri AD, Friedman EA. Natural history of heroin associated nephropathy. N Engl J Med. 1974;290:19–23.PubMedView ArticleGoogle Scholar
  28. Dettmeyer RB, Preuß J, Wollersen H, Madea B. Heroin-associated nephropathy. . Expert Opin Drug Saf Taylor & Francis; 2005;4:19–28.Google Scholar
  29. Jaffe JA, Kimmel PL. Chronic nephropathies of cocaine and heroin abuse: a critical review. Clin J Am Soc Nephrol. 2006;1:655–67.PubMedView ArticleGoogle Scholar
  30. Rao TKS, Nicastri AD, Friedman EA. Natural history of heroin-associated nephropathy. N Engl J Med Massachusetts Medical Society. 1974;290:19–23.View ArticleGoogle Scholar
  31. May DC, Helderman JH, Eigenbrodt EH, Silva FG. Chronic sclerosing glomerulopathy (heroin-associated nephropathy) in intravenous T’s and blues abusers. Am J Kidney Dis. 1986;8:404–9.PubMedView ArticleGoogle Scholar
  32. Salomon MI, Poon TP, Goldblatt M, Tchertkoff V. Renal lesions in heroin addicts. A study based on kidney biop- sies. Nephron. 1972;9:356–63.PubMedView ArticleGoogle Scholar
  33. Meador KH, Sharon Z, Lewis EJ. Renal amyloidosis and subcutaneous drug abuse. Ann Intern Med. 1979;91:565–7.PubMedView ArticleGoogle Scholar
  34. Tan AU Jr, Cohen AH, Levine BS. Renal amyloidosis in a drug abuser. J Am Soc Nephrol. 1995;5:1653–8.PubMedGoogle Scholar
  35. Manner I, Sagedal S, Røger M, Renal OI. Amyloidosis in intravenous heroin addicts with nephrotic syndrome and renal failure. Clin Nephrol. 2009;72:224–8.PubMedView ArticleGoogle Scholar
  36. Connolly JO, Gillmore JD, Lachmann HJ, Davenport A, Hawkins PN, Woolfson RG. Renal amyloidosis in intravenous drug users. QJM. 2006;99:737–42.PubMedView ArticleGoogle Scholar
  37. Cooper C, Bilbao JE, Said S, Alkhateeb H, Bizet J, Elfar A, et al. Serum amyloid a renal amyloidosis in a chronic subcutaneous (&quot;skin popping&quot;) heroin user. J. Nephropathol. Society of Diabetic Nephropathy. 2013;2:196–200.Google Scholar
  38. Sahni V, Garg D, Garg S, Agarwal SK, Singh NP. Unusual complications of heroin abuse: transverse myelitis, rhabdomyolysis, compartment syndrome, and ARF. Clin Toxicol. 2008;46:153–5.View ArticleGoogle Scholar
  39. Gupta A, Khaira A, Lata S, Agarwal SK, Tiwari SC. Rhabdomyolysis, acute kidney injury and transverse myelitis due to naive heroin exposure. Saudi J Kidney Dis Transpl. 2011;22:1223–5.PubMedGoogle Scholar
  40. Abdullah MS, AL-Waili NS, Butler G, Baban NK. Hyperbaric oxygen as an adjunctive therapy for bilateral compartment syndrome, rhabdomyolysis and acute renal failure after heroin intake. Arch Med Res. 2006;37:559–62.PubMedView ArticleGoogle Scholar
  41. Garg S, Hoenig M, Edwards EM, Bliss C, Heeren T, Tumilty S, et al. Incidence and predictors of acute kidney injury in an urban cohort of subjects with HIV and hepatitis C virus coinfection. AIDS Patient Care STDS. Mary Ann Liebert, Inc. 2011;25:135–41.Google Scholar
  42. Novick T, Liu Y, Alvanzo A, Zonderman AB, Evans MK, Crews DC. Lifetime cocaine and opiate use and chronic kidney disease. Am J Nephrol. 2016;44:447–53.PubMedPubMed CentralView ArticleGoogle Scholar
  43. Bautista JEK, Merhi B, Gregory O, Hu S, Henriksen K, Gohh R. Heroin crystal nephropathy. Clin. Kidney J. Oxford University Press. 2015;8:339–42.View ArticleGoogle Scholar
  44. Corliss RF, Mandal R, Soriano BJ. Bilateral acute necrosis of the globi pallidi and rhabdomyolysis due to combined methadone and benzodiazepine toxicity. Am J Forensic Med Pathol. 2013;34:1–4.PubMedView ArticleGoogle Scholar
  45. Hsu WY, Chiu NY, Liao YC. Rhabdomyolysis and brain ischemic stroke in a heroin-dependent male under methadone maintenance therapy. Acta Psychiatr Scand. 2009;120:76–9.PubMedView ArticleGoogle Scholar
  46. Khassawneh M, Al-Balas H. Renal impairment and hydronephrosis in a premature infant following morphine infusion: case report. Pediatr Nephrol. 2008;23:1887–8.PubMedView ArticleGoogle Scholar
  47. Glanzmann C, Frey B, Vonbach P, Meier CR. Drugs as risk factors of acute kidney injury in critically ill children. Pediatr Nephrol. 2015;1:145–51.Google Scholar
  48. Miller PJ, Farland AM, Knovich MA, Batt KM, Owen J. Successful treatment of intravenously abused oral Opana ER-induced thrombotic microangiopathy without plasma exchange. Am J Hematol. 2014;89:695–7.PubMedView ArticleGoogle Scholar
  49. Briggs M, Arguin PM. Thrombotic thrombocytopenic purpura ( TTP )– like illness associated with intravenous Opana ER abuse — Tennessee, 2012. MMWR. 2013;62:1–16.Google Scholar
  50. Nzerue CM, Hewan-Lowe K, Riley LJ. Cocaine and the kidney: a synthesis of pathophysiologic and clinical perspectives. Am J Kidney Dis. 2000;35:783–95.PubMedView ArticleGoogle Scholar
  51. Chiuech CC, Kopin IJ. Centrally mediated release by cocaine of endogenous epinephrine and norepinephrine from the sympathoadrenal medullary system of unanesthetized rats. J Pharmacol Exp Ther. 1978;205:148–54.Google Scholar
  52. Isner J, Chokshi S. Cardiovascular complications of cocaine. Curr Probl Cardiol. 1991;16:89–123.PubMedView ArticleGoogle Scholar
  53. Zimmerman JL. Cocaine intoxication. Crit Care Clin. 2012;28:517–26.PubMedView ArticleGoogle Scholar
  54. Fine DM, Garg N, Haas M, Rahman MH, Lucas GM, Scheel PJ, et al. Cocaine use and hypertensive renal changes in HIV-infected individuals. Clin J Am Soc Nephrol. 2007;2:1125–30.PubMedView ArticleGoogle Scholar
  55. Buettner M, Toennes SW, Buettner S, Bickel M, Allwinn R, Geiger H, et al. Nephropathy in illicit drug abusers: a postmortem analysis. Am J Kidney Dis Elsevier Inc. 2014;63:945–53.View ArticleGoogle Scholar
  56. Heesch C, Wilhelm C, Ristich J, Adnane J, Bontempo F, Wagner W. Cocaine activates platelets and increases the formation of circulating platelet containing microaggregates in humans. Heart. 2000;83(6):688-695. doi:10.1136/heart.83.6.688.
  57. Bemanian S, Motallebi M, Nosrati SM. Cocaine-induced renal infarction: report of a case and review of the literature. BMC Nephrol. BioMed Central. 2005;6:10.View ArticleGoogle Scholar
  58. Madhrira MM, Mohan S, Markowitz GS, Pogue VA, Cheng J-T. Acute bilateral renal infarction secondary to cocaine-induced vasospasm. Kidney Int Elsevier Masson SAS. 2009;76:576–80.View ArticleGoogle Scholar
  59. Tarrass F, Benjelloun M. Cocaine-induced acute renal failure without rhabdomyolysis. Port J Nephrol Hypert. 2009;23:65–6.Google Scholar
  60. Picazo Sánchez M, Cuxart Pérez M, Martín Romero F. Sans Lorman R. Cocaine use, high blood pressure and chronic kidney disease. Nefrologia. 2010;30:706–7.PubMedGoogle Scholar
  61. Edmondson DA, Towne JB, Foley DW, Abu-Hajir M, Kochar MS. Cocaine-induced renal artery dissection and thrombosis leading to renal infarction. Wis Med J. 2004;103:66–9.Google Scholar
  62. Furaz K, Carro CB, García AC, José AP, De TJAS. Renal infarction and acute renal failure due to cocaine use. Nefrologia. 2008;28:347–9.PubMedGoogle Scholar
  63. Gu X, Herrera GA. Thrombotic Microangiopathy in cocaine abuse – associated malignant hypertension report of 2 cases with review of the literature. Arch Pathol Lab Med. 2007;131:1817–20.PubMedGoogle Scholar
  64. Roth D, Alarcón FJ, Fernandez JA, Preston RA, Bourgoignie JJ. Acute rhabdomyolysis associated with cocaine intoxication. N. Engl. J. Med. Massachusetts medicalSociety. 1988;319:673–7.View ArticleGoogle Scholar
  65. van der Woude FJ. Cocaine use and kidney damage. Nephrol Dial Transplant. 2000;15:299–301.PubMedView ArticleGoogle Scholar
  66. Botros M, Salloum IM. Acute kidney injury associated with alcohol and cocaine abuse. Addict Disord Their Treat. 2016;15:49–51.View ArticleGoogle Scholar
  67. Connor ADO, Padilla-jones A, Gerkin RD. Levine M. Prevalence of Rhabdomyolysis in Sympathomimetic Toxicity : a Comparison of Stimulants. 2015:195–200.Google Scholar
  68. Abdul-Karim R, Ryan C, Rangel C, Emmett M. Levamisole-induced vasculitis. Proc. (Bayl. Univ. med. Cent). Baylor Health Care System. 2013;26:163–5.Google Scholar
  69. Trimarchi M, Gregorini G, Facchetti F, Morassi ML, Manfredini C, Maroldi R, et al. Cocaine-induced midline destructive lesions: clinical, radiographic, histopathologic, and serologic features and their differentiation from Wegener granulomatosis. Medicine. Google Scholar
  70. Veronese FV, Dode RSO, Friderichs M, Thomé GG, da Silva DR, Schaefer PG, et al. Cocaine/levamisole-induced systemic vasculitis with retiform purpura and pauci-immune glomerulonephritis. Brazilian J. Med. Biol. Res. = rev. bras. Pesqui. Medicas e biol. Associação Brasileira de Divulgação. Científica. 2016;49:e5244.Google Scholar
  71. Lamia R, Ati Z El, Fatma L ben, Zouaghi K, Smaoui W, Rania K, et al. case report malignant hypertension-associated thrombotic Microangiopathy following cocaine use. Saudi J Kidney Dis Transpl 2016;26:153–156.Google Scholar
  72. Carrara C, Emili S, Lin M, Alpers CE. Necrotizing and crescentic glomerulonephritis with membranous nephropathy in a patient exposed to levamisole-adulterated cocaine. Clin. Kidney J. Oxford University Press. 2016;9:234–8.View ArticleGoogle Scholar
  73. Veer TV d, Pennings E, JWC T, Korswagen L, Van der VT, Pennings E, et al. levamisole-contaminated cocaine : a hairy affair. BMJ Case Rep. 2015;2015:10–2.Google Scholar
  74. Garg L, Gupta S, Swami A, Zhang P, Louis S. Case report levamisole / cocaine induced systemic Vasculitis and immune complex glomerulonephritis. Case Reports Nephrol. 2015;2015:5.View ArticleGoogle Scholar
  75. Baptiste GG, Alexopoulos A-S, Masud T, Bonsall JM. Systemic Levamisole-Induced Vasculitis in a Cocaine User without Cutaneous Findings: A Consideration in Diagnosis. Case Rep. Med. Hindawi Publishing Corporation; 2015;2015:3.Google Scholar
  76. Ammar AT, Livak M, Witsil JC, Pharmd ATA, Livak M, Pharmd JCW. Old drug new trick : levamisole-adulterated cocaine causing acute kidney injury . Am J Emerg Med Elsevier B.V. 2015;33(309):e3–309. e4Google Scholar
  77. Luciano RL, Perazella MA. Nephrotoxic effects of designer drugs: synthetic is not better! Nat rev Nephrol. Nat Publ Group. 2014;10:314–24.Google Scholar
  78. Jones C, Little K. Hepatorenal problems presented in an urban high dependancy unit in a user of ecstasy and cocaine. Accid Emerg Nurs. 2000;8:20–3.PubMedView ArticleGoogle Scholar
  79. Kwon C, Zaritsky A, Dharnidharka VR. Transient proximal tubular renal injury following ecstasy ingestion. Pediatr Nephrol. 2003;18:820–2.PubMedView ArticleGoogle Scholar
  80. Varga MD. Adderall abuse on college campuses: a comprehensive literature review. J Evid Based Soc Work. 2012;9:293–313.PubMedView ArticleGoogle Scholar
  81. Shelton CP, Rosini JM. Multisystem organ failure and death resulting from ingestion of “Molly” (3,4-Methylenedioxymethamphetamine). J Emerg Nurs Emergency Nurses Association. 2015;41:447–50.View ArticleGoogle Scholar
  82. Santoro JD, Black JM, Lee HL. A case of rhabdomyolysis in the presence of multiple risk factors and Dextroamphetamine use. Am J Med Sci Elsevier Masson SAS. 2013;345:494–6.View ArticleGoogle Scholar
  83. Ecstasy Overdoses CDC. At a new Year’s eve rave — Los Angeles, California, 2010. MMWR. Morb Mortal Wkly Rep. 2010;59:682–6.Google Scholar
  84. Bingham C, Beaman M, Nicholls AJ, Anthony PP. Nephrology Dialysis Transplantation Necrotizing renal vasculopathy resulting in chronic renal failure after ingestion of methamphetamine and 3,4-methylenedioxymethamphetamine (‘ecstasy’). Nephrol Dial Transpl. 1998;13:2654–5.View ArticleGoogle Scholar
  85. Eldehni MT, Roberts ISD, Naik R, Vaux E. Case report of ecstasy-induced renal venous thrombosis. NDT Plus. 2010;3:459–60.PubMedPubMed CentralGoogle Scholar
  86. Lin P-Y, Lin C-C, Liu H-C, Lee M-D, Lee H-C, Ho C-S, et al. Rasburicase improves hyperuricemia in patients with acute kidney injury secondary to rhabdomyolysis caused by ecstasy intoxication and exertional heat stroke. Pediatr Crit Care Med. 2011;12:e424–7.PubMedView ArticleGoogle Scholar
  87. Nicol JJE, Yarema MC, Jones GR, Martz W, Purssell RA, MacDonald JC, et al. Deaths from exposure to paramethoxymethamphetamine in Alberta and British Columbia, Canada: a case series. Can Med Assoc J Open. 2015;3:E83–90.Google Scholar
  88. Davies O, Batajoo-Shrestha B, Sosa-Popoteur J, Olibrice M. Full recovery after severe serotonin syndrome, severe rhabdomyolysis, multi-organ failure and disseminated intravascular coagulopathy from MDMA. Acute. Hear Lung J Crit Care. 2014;43:117–9.View ArticleGoogle Scholar
  89. Armenian P, Mamantov TM, Tsutaoka BT, Gerona RRL, Silman EF, AHB W, et al. Multiple MDMA (ecstasy) overdoses at a rave event: a case series. J Intensive Care Med. 2012;28:252–8.PubMedView ArticleGoogle Scholar
  90. De Fallois J, Regenthal R, Petros S. Fulminant thrombotic thrombocytopenic purpura (TTP): association with amphetamine consumption? Ann Hematol. 2015;94:337–8.PubMedView ArticleGoogle Scholar
  91. Miotto K, Striebel J, Cho AK, Wang C. Clinical and pharmacological aspects of bath salt use: a review of the literature and case reports. Drug Alcohol Depend. 2013;132:1–12.PubMedView ArticleGoogle Scholar
  92. Borek HA, Holstege CP. Hyperthermia and multiorgan failure after abuse of “bath salts” containing 3,4-Methylenedioxypyrovalerone. Ann Emerg Med. 2012;60:103–5.PubMedView ArticleGoogle Scholar
  93. Peng T-R, Lee M-C, T-W W, Lan C-C. Suspected ketamine-associated lower Uri- nary tract symptoms. Urol J. 2012;11:1508–10.Google Scholar
  94. Huang L-K, Wang J-H, Shen S-H, Lin ATL, Chang C-Y. Evaluation of the extent of ketamine-induced uropathy: the role of CT urography. Postgrad Med J. 2014;90:185–90.PubMedPubMed CentralView ArticleGoogle Scholar
  95. Tran VH, Nelson M, Nogar J, Bramante RM. Bilateral hydronephrosis and cystitis resulting from. West J Emerg Med. 2014;15:382–4.PubMedPubMed CentralView ArticleGoogle Scholar
  96. Chenoweth JA, Gerona RR, Ford JB, Sutter ME, Rose JS, Albertson TE, et al. Altered mental status and end organ damage associated with the use of Gacyclidine: a case series. J Med Toxicol. 2015;11:115–20.PubMedView ArticleGoogle Scholar
  97. Argamany JR, Reveles KR, Duhon B. Synthetic cannabinoid hyperemesis resulting in rhabdomyolysis and acute renal failure. Am. J. Emerg. Med. 2016;34(765):e1–765.e2.Google Scholar
  98. Bhanushali GK, Jain G, Fatima H, Leisch LJ, Thornley-Brown DAKI. Associated with synthetic cannabinoids: a case series. Clin J Am Soc Nephrol. 2013;8:523–6.PubMedView ArticleGoogle Scholar
  99. Buser GL, Gerona RR, Horowitz BZ, Vian KP, Troxell ML, Hendrickson RG, et al. Acute kidney injury associated with smoking synthetic cannabinoid. Clin Toxicol. 2014;52:664–73.View ArticleGoogle Scholar
  100. Centers for Disease Control and Prevention. Acute kidney injury associated with synthetic cannabinoid use — multiple states. MMWR. Morb Mortal Wkly Rep. 2013;62:93–8.Google Scholar
  101. Gudsoorkar VS, Perez JAA. New differential diagnosis: synthetic cannabinoids-associated acute renal failure. Methodist Debakey Cardiovasc J. 2015;11:189–91.PubMedPubMed CentralView ArticleGoogle Scholar
  102. Kazory A, Aiyer R. Synthetic marijuana and acute kidney injury: an unforeseen association. Clin Kidney J. 2013;6:330–3.PubMedPubMed CentralView ArticleGoogle Scholar
  103. Katz KD, Leonetti AL, Bailey BC, Surmaitis RM, Eustice ER, Kacinko S, et al. Case Series of Synthetic Cannabinoid Intoxication from One Toxicology Center. West. J. Emerg. Med. California Chapter of the American Academy of Emergency Medicine (Cal/AAEM); 2016;17:290–4.Google Scholar
  104. Sherpa D, Paudel BM, Subedi BH, Chow RD. Synthetic cannabinoids: the multi-organ failure and metabolic derangements associated with getting high. J community Hosp Intern Med Perspect Co-Action Publishing. 2015;5:27540.View ArticleGoogle Scholar
  105. Srisung W, Jamal F, Prabhakar S. Synthetic cannabinoids and acute kidney injury. Proc. (Bayl. Univ. Med. Cent). 2015;28:475–7.View ArticleGoogle Scholar
  106. Thornton SL, Wood C, Friesen MW, Gerona RR. Synthetic cannabinoid use associated with acute kidney injury. Clin. Toxicol. (Phila). 2013;51:189–90.View ArticleGoogle Scholar
  107. Zhao A, Tan M, Maung A, Salifu M, Mallappallil M. Rhabdomyolysis and acute kidney injury requiring dialysis as a result of concomitant use of atypical neuroleptics and synthetic cannabinoids. Case reports Nephrol. 2015;2015:235982.View ArticleGoogle Scholar
  108. Penders TM, Gestring RE, Vilensky DA. Excited delirium following use of synthetic cathinones (bath salts). Gen Hosp Psychiatry. 2012;34:647–50.PubMedView ArticleGoogle Scholar
  109. Smith CD, Williams M, Shaikh M. Novel psychoactive substances: a novel clinical challenge. BMJ Case Rep. 2013;2013:1–3.Google Scholar
  110. Rhidian R, Babu A. Acute kidney injury requiring haemodialysis following ingestion of mephedrone. BMJ case rep. BMJ. Group. 2013;2013:7974.Google Scholar
  111. Sutamtewagul G, Sood V, Nugent K. Sympathomimetic syndrome, choreoathetosis, and acute kidney injury following “bath salts” injection. Clin Nephrol. 2014;81:63–6.PubMedView ArticleGoogle Scholar
  112. Murray BL, Murphy CM, Beuhler MC. Death following recreational use of designer drug “bath salts” containing 3,4-Methylenedioxypyrovalerone (MDPV). J. Med. Toxicol. 2012;8:69–75.PubMedPubMed CentralView ArticleGoogle Scholar
  113. Feng G, Luo Q, Guo E, Yao Y, Yang F, Zhang B, et al. Multiple organ dysfunction syndrome, an unusual complication of heroin intoxication: a case report and review of literature. Int. J. Clin. Exp. Pathol. e-Century Publishing Corporation. 2015;8:11826–30.Google Scholar
  114. Ago M, Ago K, Hara K, Kashimura S, Ogata M. Toxicological and histopathological analysis of a patient who died nine days after a single intravenous dose of methamphetamine: a case report. Legal Med. 2006;8:235–9.PubMedView ArticleGoogle Scholar
  115. Eede H, Vanden MLJ, Touw DJ, Norris EM. Rhabdomyolysis in MDMA intoxication: A rapid and underestimated killer. “clean” Ecstasy, a safe party drug. J. Emerg. Med. Elsevier Inc. 2012;42:655–8.View ArticleGoogle Scholar
  116. Vakde T, Diaz M, Uday K, Duncalf R. Rapidly reversible multiorgan failure after ingestion of “Molly” (pure 3,4-methylenedioxymethamphetamine): a case report. J Med Case Rep. BioMed Central. 2014;8:204.View ArticleGoogle Scholar
  117. Eilert RJ, Kliewer ML. Methamphetamine-induced Rhabdomyolysis. Int Anesthesiol Clin. Spring. 2011;49(2):52-6. doi:10.1097/AIA.0b013e3181ffc0e5.
  118. Aithal S, Marley N, Venkat-Raman G. An unusual non-immunological cause of renal pulmonary syndrome. Clin Nephrol. 2009;72:322–5.PubMedView ArticleGoogle Scholar
  119. Alfaro R, Vasavada N, Paueksakon P, Hernandez GT, Aronoff GR. Cocaine-induced acute interstitial nephritis: a case report and review of the literature. J Nephropathol Society of Diabetic Nephropathy. 2013;2:204–9.Google Scholar
  120. Bahaa Aldeen M, Talibmamury N, Alalusi S, Nadham O, Omer AR, Smalligan RD. When coke is not hydrating: cocaine-induced acute interstitial nephritis. J. Investig. Med. High impact case reports SAGE Publications. 2014;2:1–4.Google Scholar
  121. Fabbian F, Pala M, De Giorgi A, Tiseo R, Molino C, Mallozzi Menegatti A, et al. Left kidney: an unusual site of cocaine-related renal infarction. A case report. Eur Rev Med Pharmacol Sci. 2012;16(Suppl 1):30–3.PubMedGoogle Scholar
  122. Gelpi R, Taco O, Goma M, Torras J, Poveda R, Alvarez T, et al. Evolución natural de la función renal en el anciano: análisis de factores de mal pronóstico asociados a la enfermedad renal crónica. NEfrología. 2013;33:609–11.PubMedGoogle Scholar
  123. Goel N, Pullman JM, Coco M. Cocaine and kidney injury: a kaleidoscope of pathology. Clin Kidney J Oxford University Press. 2014;7:513–7.View ArticleGoogle Scholar
  124. Goldberg A. Superimposed cocaine-induced rhabdomyolysis in a patient with aortic dissection rhabdomyolysis. A A Case Reports. 2015;4:75–7.PubMedView ArticleGoogle Scholar
  125. Hirachan P, Agarwal R, Wagner B. Cocaine: a rare cause of left-sided renal infarction. J. Investig. Med. High impact case reports. SAGE Publications. 2015;3:1–4.View ArticleGoogle Scholar
  126. Rivero M, Karlic A, Navaneethan SD, Singh S. Possible cocaine-induced acute renal failure without rhabdomyolysis. J Nephrol. 2006;19:108–10.PubMedGoogle Scholar
  127. Sirvent AE, Andrada E, Gallego JA, Padilla I, Enríquez R, Andrada E, et al. Goodpasture ’ s syndrome in a patient using cocaine. Clin Nephrol. 2007;68:182–5.PubMedView ArticleGoogle Scholar
  128. Zoghby Z, Sekhon IS, Miller DV, Sethi S. Cocaine, loin pain, and renal vein thrombosis. Am J Kidney Dis. 2007;49:859–61.PubMedView ArticleGoogle Scholar
  129. Carlson AQ, Tuot DS, Jen K-Y, Butcher B, Graf J, Sam R, et al. Pauci-immune glomerulonephritis in individuals with disease associated with levamisole-adulterated cocaine a series of 4 cases. Medicine (Baltimore). 2014;93:290–7.View ArticleGoogle Scholar
  130. Díaz HÁ, Callejo AIM, Rodríguez JFG, Pazos LR, Buela IG, Barrera AMB, et al. ANCA-positive vasculitis induced by levamisole-adulterated cocaine and nephrotic syndrome: The kidney as an unusual target. Am. J. Case Rep. International Scientific Literature, Inc. 2013;14:557–61.Google Scholar
  131. Liu Y-WJ, Mutnuri S, Siddiqui SB, Weikle GR, Oladipo O, Ganti N, et al. Levamisole-adulterated cocaine nephrotoxicity. Am J Clin Pathol. 2016;145:720–6.PubMedView ArticleGoogle Scholar
  132. Moinuddin I, Madhrira M, Bracamonte E, Thajudeen B, Sussman A. Research and Practice Membranous nephropathy with crescents associated with levamisole-induced MPO-ANCA vasculitis. Pathol. -- Res. Pract. Elsevier GmbH. 2016;212:650–3.View ArticleGoogle Scholar
  133. Wojciechowski D, Kallakury B, Nouri P, Report CA. Case of cocaine-induced acute interstitial nephritis. Am J Kidney Dis. 2008;52:792–5.PubMedView ArticleGoogle Scholar
  134. Zuin M, Giorgini A, Selmi C, Battezzati PM, Cocchi CA, Crosignani A, et al. Acute liver and renal failure during treatment with buprenorphine at therapeutic dose. Dig Liver Dis. 2009;41:2008–10.Google Scholar
  135. Eiden C, Ripault MP, Larrey D, Faillie JL, Pinzani V, Pageaux GP, et al. Acute hepatitis and renal failure related to intranasal buprenorphine misuse: case report and analysis of cases reported to the French network for drug monitoring. Ann Pharmacother. 2013;47:1721–6.PubMedView ArticleGoogle Scholar
  136. Jabr F, Yu l. Thrombotic microangiopathy associated with opana er intravenous abuse. Leban. Med J. 2016;64:64–6.Google Scholar
  137. Chaudhari S, Wankhedkar K, Popis-matejak B, Baumstein D. Methadone for Fun Sake. Kidneys Are at Stake !!! Am. J. Ther.;23. 2016;23:e1108–9.View ArticleGoogle Scholar
  138. Riederer AM, Campleman SL, Carlson RG, Boyer EW, Manini AF, Wax PM, et al. Acute poisonings from synthetic cannabinoids - 50 U.S. toxicology investigators consortium registry sites, 2010-2015. MMWR. Morb Mortal Wkly Rep. 2016;65:692–5.View ArticleGoogle Scholar
  139. Kosmadakis G, Michail O, Georgoulias C, Filiopoulos V, Papadopoulou P, Michail S. Acute kidney injury due to rhabdomyolysis in narcotic drug users. Int J Artif Organs. 2011;34:584–8.PubMedView ArticleGoogle Scholar
  140. Aghabiklooei A, Edalatparvar M, Zamani N, Mostafazadeh B. Prognostic factors in acute methadone toxicity: A 5-year study. J Toxicol Hindawi Publishing Corporation; 2014;2014:341826.Google Scholar
  141. McGrath MM, Isakova T, Rennke HG, Mottola AM, Laliberte KA, Niles JL. Contaminated cocaine and Antineutrophil cytoplasmic antibody ­ associated disease. Am. Soc. Nephrol. American Society of Nephrology. 2011;6:2799–805.View ArticleGoogle Scholar
  142. Liechti ME, Kunz I, Kupferschmidt H. Acute medical problems due to ecstasy use. Case-series of emergency department visits. Swiss Med Wkly Off J Swiss Soc Infect Dis Swiss Soc Intern Med Swiss Soc Pneumol. 2005;135:652–7.Google Scholar
  143. Jones ESW, Rayner BL. Hypertension, end-stage renal disease and mesangiocapillary glomerulonephritis in methamphetamine users. South African. Med J. 2015;105:199–201.Google Scholar
  144. Price SL, Fisher C, Kumar R, Hilgerson A. Cannabinoid Hyperemesis Syndrome as the Underlying Cause of Intractable Nausea and Vomiting. J. Am. Osteopath. Assoc. American Osteopathic Association; 2011;111:166.Google Scholar
  145. Baron M, Haymann J-P, Wolfromm A, Rondeau E, Mesnard L. The case | the smoker and the nephrologist. Kidney Int. 2011;79:1385–6.PubMedView ArticleGoogle Scholar
  146. Abodunde OA, Nakda J, Nweke N, Levaka R. Cannabinoid hyperemesis syndrome presenting with recurrent acute. Ren Fail. 2013;4:173–5.Google Scholar
  147. Chang C-C, Hsu Y-J, Chu P, Lin S-H. Repetitive vomiting and acute renal failure as the presenting features of cannabinoid hyperemesis syndrome. J Med Sci. 2013;33:163–5.Google Scholar
  148. Ukaigwe A, Karmacharya P, Donato AA. Gut gone to pot: a case of cannabinoid hyperemesis syndrome due to K2, a synthetic cannabinoid. Case rep. Emerg Med. 2014:167098.Google Scholar
  149. Srihari P, Liu M, Punzell S, Shebak SS, Rea WS. Cannabinoid Hyperemesis Syndrome Associated With Compulsive Showering and Acute Kidney Injury. Prim. care companion CNS Disord. Physicians Postgraduate Press, Inc.; 2016;18.Google Scholar
  150. Wiergowski M, Anand J, Krzyżanowski M, Jankowski Z. Acute methoxetamine and amphetamine poisoning with fatal outcome: a case report. Int J Occup Med Environ Health. 2014;27:683–90.PubMedView ArticleGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement